Search Results 701-710 of 18064 for Alopecia

1. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other non-clinically significant adverse events. - Any of the ...

2. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. Note: If subjects ...

3. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia). Washout from trastuzumab or hormonal therapy is not required. Participants who are currently receiving any other investigational agents. History ...

4. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

5. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   ... alopecia and oxaliplatin induced neurotoxicity ≤ grade 2; Albumin levels > 2.5; Any of the following: Pregnant women; Nursing women; Men or women of ...

6. Study to Evaluate the Safety, Tolerability and Antitumor Activity of Anti-B7-H3 Car-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma - Mayo Clinic

   The toxicity and side effects caused by previous treatment have not recovered to ≤ grade 1 (per CTCAE 5.0); except for alopecia and other tolerable events ...

7. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   Acute effects of any prior therapy resolved to baseline severity or to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 (except for alopecia, ...

8. A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib - Mayo Clinic

   ... alopecia and Grade 2, prior platinum-therapy related neuropathy. As judged by the investigator, active gastrointestinal disease or other condition that will ...

9. A Study to Test the Addition of berzosertib to Usual Radiation Treatment for Chemotherapy-Resistant Breast Cancer - Mayo Clinic

   Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

10. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

    Participation eligibility · Patients with vitiligo or alopecia; · Patients with hypothyroidism (e.g., following Hashimoto syndrome), stable on hormone replacement ...